Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Cancer - 1 Mar 2017

Talhouk Aline, McConechy Melissa K, Leung Samuel, Yang Winnie, Lum Amy, Senz Janine, Boyd Niki, Pike Judith, Anglesio Michael, Kwon Janice S, Karnezis Anthony N, Huntsman David G, Gilks C Blake, McAlpine Jessica N

Abstract excerpt

BACKGROUND: Classification of endometrial carcinomas (ECs) by morphologic features is irreproducible and imperfectly reflects tumor biology. The authors developed the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), a molecular classification system based on The Cancer Genome Atlas genomic subgroups, and sought to confirm both feasibility and prognostic ability in a new, large cohort of ECs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to Endometrial Neoplasms

Share to Microsatellite Instability

Share to Neoplasm Staging

Share to Pathology, Molecular

Share to Poly-ADP-Ribose Binding Proteins

Source

Identifiers

PMID: 28061006
DOI: 10.1002/cncr.30496

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.PMID 28061006Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomasSemantic proximity Read ↗

A clinically applicable molecular-based classification for endometrial cancers.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.Semantic proximity Read ↗

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.Semantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.